measles

GPTKB entity

Statements (60)
Predicate Object
gptkbp:instance_of gptkb:disease
gptkbp:associated_virus gptkb:paramyxovirus
gptkbp:caused_by measles virus
gptkbp:characteristic_rash maculopapular rash
gptkbp:community_health surveillance systems
community education
vaccination campaigns
gptkbp:complication gptkb:pneumonia
gptkb:multiple_sclerosis
diarrhea
gptkbp:contagious_period 4 days before to 4 days after rash
gptkbp:death higher in immunocompromised individuals
higher in malnourished children
gptkbp:diagnosis clinical evaluation
serological testing
PCR testing
gptkbp:diseases common in unvaccinated populations
frequent in crowded areas
gptkbp:epidemiology more common in winter and spring
gptkbp:global_incidence over 140,000 deaths in 2018
gptkbp:goal elimination of measles in many regions by 2020
global vaccination coverage increase
gptkbp:historical_significance first described by Persian physician Rhazes
https://www.w3.org/2000/01/rdf-schema#label measles
gptkbp:immunity_duration lifetime immunity after infection
long-lasting immunity after vaccination
gptkbp:incubation_period 10 to 14 days
gptkbp:is_documented_in 9th century
gptkbp:is_vulnerable_to gptkb:measles,_mumps,_and_rubella_vaccine_(MMR)
developed in the 1960s
measles vaccine
children at 12-15 months
over 95% after two doses
second dose at 4-6 years
gptkbp:koplik_spots_appearance inside the mouth
gptkbp:koplik_spots_significance early sign of measles
gptkbp:prevention vaccination
gptkbp:rash_appearance 3 to 5 days after fever
gptkbp:region gptkb:Africa
gptkb:Europe
Americas
Eastern Mediterranean
Western Pacific
South-East Asia
gptkbp:risk_factor travel to endemic areas
lack of vaccination
close contact with infected individuals
gptkbp:seed_dispersal single-stranded RNA
gptkbp:symptoms gptkb:Koplik_spots
cough
fever
sore throat
runny nose
rash
high fever
gptkbp:transmission airborne droplets
gptkbp:treatment supportive care
vitamin A supplementation
gptkbp:bfsParent gptkb:M-M-R_II
gptkbp:bfsLayer 5